Format

Send to

Choose Destination
BMJ Open. 2017 Jul 10;7(7):e015344. doi: 10.1136/bmjopen-2016-015344.

Bubble continuous positive airway pressure in the treatment of severe paediatric pneumonia in Malawi: a cost-effectiveness analysis.

Author information

1
Department of Pediatrics, University of California, San Francisco, California, USA.
2
Philip R Lee Institute for Health Policy Studies, University of California, San Francisco, California, USA.
3
Health Strategies International, Oakland, USA.
4
Philip R. Lee Institute for Health Policy Studies and Global Health Economics Consortium, University of California, San Francisco, California, USA.

Abstract

OBJECTIVES:

Pneumonia is the largest infectious cause of death in children under 5 years globally, and limited resource settings bear an overwhelming proportion of this disease burden. Bubble continuous positive airway pressure (bCPAP), an accepted supportive therapy, is often thought of as cost-prohibitive in these settings. We hypothesise that bCPAP is a cost-effective intervention in a limited resource setting and this study aims to determine the cost-effectiveness of bCPAP, using Malawi as an example.

DESIGN:

Cost-effectiveness analysis.

SETTING:

District and central hospitals in Malawi.

PARTICIPANTS:

Children aged 1 month-5 years with severe pneumonia, as defined by WHO criteria.

INTERVENTIONS:

Using a decision tree analysis, we compared standard of care (including low-flow oxygen and antibiotics) to standard of care plus bCPAP.

PRIMARY AND SECONDARY OUTCOME MEASURES:

For each treatment arm, we determined the costs, clinical outcomes and averted disability-adjusted life years (DALYs). We assigned input values from a review of the literature, including applicable clinical trials, and calculated an incremental cost-effectiveness ratio (ICER).

RESULTS:

In the base case analysis, the cost of bCPAP per patient was $15 per day and $41 per hospitalisation, with an incremental net cost of $64 per pneumonia episode. bCPAP averts 5.0 DALYs per child treated, with an ICER of $12.88 per DALY averted compared with standard of care. In one-way sensitivity analyses, the most influential uncertainties were case fatality rates (ICER range $9-32 per DALY averted). In a multi-way sensitivity analysis, the median ICER was $12.97 per DALY averted (90% CI, $12.77 to $12.99).

CONCLUSION:

bCPAP is a cost-effective intervention for severe paediatric pneumonia in Malawi. These results may be used to inform policy decisions, including support for widespread use of bCPAP in similar settings.

KEYWORDS:

health economics; paediatric intensive & critical care; paediatric thoracic medicine; respiratory infections; tropical medicine

PMID:
28698327
PMCID:
PMC5734302
DOI:
10.1136/bmjopen-2016-015344
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center